title: Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
abstract: A randomized, four-way cross-over design was used to assess the disposition of the cardioprotective agent, dexrazoxane, in four male beagle dogs following single I.V. administration of 10, 25, 50, and 100 mg kg-1 doses. Parent drug was quantified in plasma and urine with a validated high-pressure liquid chromatographic-electrochemical assay. A two-compartment open model adequately described the dexrazoxane plasma concentration versus time data. The terminal half-life ranged between 1.1 and 1.3 h and the apparent steady-state distribution volume was 0.67 L kg-1. The systemic clearance (CL) ranged from 10.3 to 11.5 mL min-1 kg-1, while estimates of renal clearance approximated the glomerular filtration rate (GFR approximately 3.2-4.9 mL min-1 kg-1). Over the dose range evaluated, CL was dose independent (ANOVA, p = 0.33), while concentration at the end of infusion (Cend) and the area under the concentration versus time curve (AUC) were directly proportional to the dose (r > 0.999). The blood cell to plasma partitioning ratio was approximately 0.517 and drug was essentially unbound to plasma proteins (fu approximately 0.95). Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively. These results suggest a relatively small drug distribution space (approximately equal to total-body water) and low tissue and plasma protein binding. In light of the low plasma protein binding and extraction ratio exhibited by dexrazoxane, metabolic capacity and renal function would appear to be the predominant variables affecting the CL of this drug. The constancy of the half-life, CL, and VSS with increasing dose indicates dose-independent disposition for dexrazoxane. Thus a linear increase in the systemic exposure can be predicted over this dose range.
authors.affiliation: Department of Clinical Pharmacology, Pharmacia Inc., Columbus, OH 43216, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Baldwin
authors.forename: R C
authors.initials: RC
authors.lastname: Lewis
authors.forename: B A
authors.initials: BA
authors.lastname: Phillips
authors.forename: S K
authors.initials: SK
authors.lastname: Overmyer
authors.forename: N Z
authors.initials: NZ
authors.lastname: Hatfield
authors.forename: P K
authors.initials: PK
authors.lastname: Narang
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001798:Blood Proteins / Q000378:metabolism; D002317:Cardiovascular Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004563:Electrochemistry; D006207:Half-Life; D007275:Injections, Intravenous; D008297:Male; D011485:Protein Binding; D011929:Razoxane / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
chemical_list: D001798:Blood Proteins; D002317:Cardiovascular Agents; D011929:Razoxane